CGRP and migraine: Could PACAP play a role too?

Neuropeptides

Volumn 47, Issue 6, 2013, Pages 451-461

  Kaiser, Eric A ^a   Russo, Andrew F ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

CGRP; Migraine; Neuropeptides; PACAP

Indexed keywords

AMITRIPTYLINE; BIBN 4096; BOTULINUM TOXIN; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; MAXADILAN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OLCEGEPANT; PLACEBO; PROPRANOLOL; RECEPTOR ACTIVITY MODIFYING PROTEIN 1; RIZATRIPTAN; SUMATRIPTAN; TELCAGEPANT; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ANALGESIA; ANIMAL BEHAVIOR; AVERSION; CENTRAL NERVOUS SYSTEM SENSITIZATION; FLUSHING; HUMAN; HYPOPHYSIS; MIGRAINE; MUSCLE TIGHTNESS; NEUROGENIC INFLAMMATION; NOCICEPTION; NONHUMAN; PAIN; PARESTHESIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SUBUNIT; REGULATORY MECHANISM; REVIEW; RODENT; SENSITIZATION; SIDE EFFECT; SPREADING CORTICAL DEPRESSION; THORAX DISEASE;

RODENTIA;

CGRP; MIGRAINE; NEUROPEPTIDES; PACAP;

ANIMALS; BRAIN; CALCITONIN GENE-RELATED PEPTIDE; CENTRAL NERVOUS SYSTEM SENSITIZATION; HUMANS; MICE; MIGRAINE DISORDERS; NOCICEPTION; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RATS;

EID: 84888016627     PISSN: 01434179     EISSN: 15322785     Source Type: Journal    
DOI: 10.1016/j.npep.2013.10.010     Document Type: Review

References (194)

1. Amara S.G., Jonas V., Rosenfeld M.G., Ong E.S., Evans R.M. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 1982, 298:240-244.
2. Amara S.G., Arriza J.L., Leff S.E., Swanson L.W., Evans R.M., Rosenfeld M.G. Expression in brain of a messenger RNA encoding a novel neuropeptide homologous to calcitonin gene-related peptide. Science 1985, 229:1094-1097.
3. Anttila V., Stefansson H., Kallela M., Todt U., Terwindt G.M., Calafato M.S., Nyholt D.R., Dimas A.S., Freilinger T., Muller-Myhsok B., Artto V., Inouye M., Alakurtti K., Kaunisto M.A., Hamalainen E., de Vries B., Stam A.H., Weller C.M., Heinze A., Heinze-Kuhn K., Goebel I., Borck G., Gobel H., Steinberg S., Wolf C., Bjornsson A., Gudmundsson G., Kirchmann M., Hauge A., Werge T., Schoenen J., Eriksson J.G., Hagen K., Stovner L., Wichmann H.E., Meitinger T., Alexander M., Moebus S., Schreiber S., Aulchenko Y.S., Breteler M.M., Uitterlinden A.G., Hofman A., van Duijn C.M., Tikka-Kleemola P., Vepsalainen S., Lucae S., Tozzi F., Muglia P., Barrett J., Kaprio J., Farkkila M., Peltonen L., Stefansson K., Zwart J.A., Ferrari M.D., Olesen J., Daly M., Wessman M., van den Maagdenberg A.M., Dichgans M., Kubisch C., Dermitzakis E.T., Frants R.R., Palotie A. Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. Nat. Genet. 2010, 42:869-873.
4. Archbold J.K., Flanagan J.U., Watkins H.A., Gingell J.J., Hay D.L. Structural insights into RAMP modification of secretin family G protein-coupled receptors: implications for drug development. Trends Pharmacol. Sci. 2011, 32:591-600.
5. Asghar M.S., Hansen A.E., Amin F.M., van der Geest R.J., Koning P., Larsson H.B., Olesen J., Ashina M. Evidence for a vascular factor in migraine. Ann. Neurol. 2011, 69:635-645.
6. Ayata C. Cortical spreading depression triggers migraine attack: pro. Headache 2010, 50:725-730.
7. Ayata C., Jin H., Kudo C., Dalkara T., Moskowitz M.A. Suppression of cortical spreading depression in migraine prophylaxis. Ann. Neurol. 2006, 59:652-661.
8. Barwell J., Gingell J.J., Watkins H.A., Archbold J.K., Poyner D.R., Hay D.L. Calcitonin and calcitonin receptor-like receptors: common themes with family B GPCRs?. Br. J. Pharmacol. 2012, 166:51-65.
9. Baun M., Hay-Schmidt A., Edvinsson L., Olesen J., Jansen-Olesen I. Pharmacological characterization and expression of VIP and PACAP receptors in isolated cranial arteries of the rat. Eur. J. Pharmacol. 2011, 670:186-194.
10. Baun M., Pedersen M.H., Olesen J., Jansen-Olesen I. Dural mast cell degranulation is a putative mechanism for headache induced by PACAP-38. Cephalalgia 2012, 32:337-345.
11. Bellamy J., Bowen E.J., Russo A.F., Durham P.L. Nitric oxide regulation of calcitonin gene-related peptide gene expression in rat trigeminal ganglia neurons. Eur. J. Neurosci. 2006, 23:2057-2066.
12. Bellamy J.L., Cady R.K., Durham P.L. Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients. Headache 2006, 46:24-33.
13. Bolay H., Reuter U., Dunn A.K., Huang Z., Boas D.A., Moskowitz M.A. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat. Med. 2002, 8:136-142.
14. Boni L.J., Ploug K.B., Olesen J., Jansen-Olesen I., Gupta S. The in vivo effect of VIP, PACAP-38 and PACAP-27 and mrna expression of their receptors in rat middle meningeal artery. Cephalalgia 2009, 29:837-847.
15. Borzsei R., Mark L., Tamas A., Bagoly T., Bay C., Csanaky K., Banki E., Kiss P., Vaczy A., Horvath G., Nemeth J., Szauer E., Helyes Z., Reglodi D. Presence of pituitary adenylate cyclase activating polypeptide-38 in human plasma and milk. Eur. J. Endocrinol. 2009, 160:561-565.
16. Bourgault S., Vaudry D., Botia B., Couvineau A., Laburthe M., Vaudry H., Fournier A. Novel stable PACAP analogs with potent activity towards the PAC1 receptor. Peptides 2008, 29:919-932.
17. Bove G.M., Moskowitz M.A. Primary afferent neurons innervating guinea pig dura. J. Neurophysiol. 1997, 77:299-308.
18. Brain S.D., Grant A.D. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol. Rev. 2004, 84:903-934.
19. Brennan K.C., Charles A. An update on the blood vessel in migraine. Curr. Opin. Neurol. 2010, 23:266-274.
20. Burstein R., Yamamura H., Malick A., Strassman A.M. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J. Neurophysiol. 1998, 79:964-982.
21. Bussone G. Clinical considerations on chronic migraine, pharmacoresistance and refractoriness. Neurol. Sci. 2010, 31(Suppl 1):S83-S85.
22. Cady R.K., Vause C.V., Ho T.W., Bigal M.E., Durham P.L. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache 2009, 49:1258-1266.
23. Campeau S., Watson S.J. Connections of some auditory-responsive posterior thalamic nuclei putatively involved in activation of the hypothalamo-pituitary-adrenocortical axis in response to audiogenic stress in rats: an anterograde and retrograde tract tracing study combined with fos expression. J. Comp. Neurol. 2000, 423:474-491.
24. Cao H., Zhang Y.Q. Spinal glial activation contributes to pathological pain states. Neurosci. Biobehav. Rev. 2008, 32:972-983.
25. Capuano A., De Corato A., Lisi L., Tringali G., Navarra P., Dello Russo C. Proinflammatory-activated trigeminal satellite cells promote neuronal sensitization: relevance for migraine pathology. Mol. Pain 2009, 5:43.
26. Chan K.Y., Baun M., de Vries R., van den Bogaerdt A.J., Dirven C.M., Danser A.H., Jansen-Olesen I., Olesen J., Villalon C.M., MaassenVanDenBrink A., Gupta S. Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery. Cephalalgia 2011, 31:181-189.
27. Charbit A.R., Akerman S., Holland P.R., Goadsby P.J. Neurons of the dopaminergic/calcitonin gene-related peptide A11 cell group modulate neuronal firing in the trigeminocervical complex: an electrophysiological and immunohistochemical study. J. Neurosci. 2009, 29:12532-12541.
28. Charles A. The evolution of a migraine attack - a review of recent evidence. Headache 2013, 53:413-419.
29. Chasman D.I., Schurks M., Anttila V., de Vries B., Schminke U., Launer L.J., Terwindt G.M., van den Maagdenberg A.M., Fendrich K., Volzke H., Ernst F., Griffiths L.R., Buring J.E., Kallela M., Freilinger T., Kubisch C., Ridker P.M., Palotie A., Ferrari M.D., Hoffmann W., Zee R.Y., Kurth T. Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nat. Genet. 2011, 43:695-698.
30. Christiansen I., Thomsen L.L., Daugaard D., Ulrich V., Olesen J. Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura. Cephalalgia 1999, 19:660-667.
31. Christopoulos A., Christopoulos G., Morfis M., Udawela M., Laburthe M., Couvineau A., Kuwasako K., Tilakaratne N., Sexton P.M. Novel receptor partners and function of receptor activity-modifying proteins. J. Biol. Chem. 2003, 278:3293-3297.
32. Colonna D.M., Meng W., Deal D.D., Busija D.W. Calcitonin gene-related peptide promotes cerebrovascular dilation during cortical spreading depression in rabbits. Am. J. Physiol. 1994, 266:H1095-H1102.
33. Connor K.M., Shapiro R.E., Diener H.C., Lucas S., Kost J., Fan X., Fei K., Assaid C., Lines C., Ho T.W. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 2009, 73:970-977.
34. Couch J.R. Update on chronic daily headache. Curr. Treat. Options Neurol. 2011, 13:41-55.
35. Csati A., Tajti J., Kuris A., Tuka B., Edvinsson L., Warfvinge K. Distribution of vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, nitric oxide synthase, and their receptors in human and rat sphenopalatine ganglion. Neuroscience 2012, 202:158-168.
36. De Corato A., Lisi L., Capuano A., Tringali G., Tramutola A., Navarra P., Dello Russo C. Trigeminal satellite cells express functional calcitonin gene-related peptide receptors, whose activation enhances interleukin-1beta pro-inflammatory effects. J. Neuroimmunol. 2011, 237:39-46.
37. de Lacalle S., Saper C.B. Calcitonin gene-related peptide-like immunoreactivity marks putative visceral sensory pathways in human brain. Neuroscience 2000, 100:115-130.
38. Diener H.C. Rpr100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Cephalalgia 2003, 23:183-185.
39. Diener H.C., Lampl C., Reimnitz P., Voelker M. Aspirin in the treatment of acute migraine attacks. Expert Rev. Neurother. 2006, 6:563-573.
40. Dobolyi A., Irwin S., Makara G., Usdin T.B., Palkovits M. Calcitonin gene-related peptide-containing pathways in the rat forebrain. J. Comp. Neurol. 2005, 489:92-119.
41. Eberhardt M., Hoffmann T., Sauer S.K., Messlinger K., Reeh P.W., Fischer M.J. Calcitonin gene-related peptide release from intact isolated dorsal root and trigeminal ganglia. Neuropeptides 2008, 42:311-317.
42. Ebersberger A., Averbeck B., Messlinger K., Reeh P.W. Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro. Neuroscience 1999, 89:901-907.
43. Ebersberger A., Charbel Issa P., Vanegas H., Schaible H.G. Differential effects of calcitonin gene-related peptide and calcitonin gene-related peptide 8-37 upon responses to N-methyl-d-aspartate or (r,s)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate in spinal nociceptive neurons with knee joint input in the rat. Neuroscience 2000, 99:171-178.
44. Edvinsson L., Alm R., Shaw D., Rutledge R.Z., Koblan K.S., Longmore J., Kane S.A. Effect of the CGRP receptor antagonist bibn4096bs in human cerebral, coronary and omental arteries and in SK-N-MC cells. Eur. J. Pharmacol. 2002, 434:49-53.
45. Edvinsson L., Eftekhari S., Salvatore C.A., Warfvinge K. Cerebellar distribution of calcitonin gene-related peptide (CGRP) and its receptor components calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1 (RAMP1) in rat. Mol. Cell. Neurosci. 2011, 46:333-339.
46. Eftekhari S., Salvatore C.A., Calamari A., Kane S.A., Tajti J., Edvinsson L. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience 2010, 169:683-696.
47. Eltorp C.T., Jansen-Olesen I., Hansen A.J. Release of calcitonin gene-related peptide (CGRP) from guinea pig dura mater in vitro is inhibited by sumatriptan but unaffected by nitric oxide. Cephalalgia 2000, 20:838-844.
48. Erdling A., Sheykhzade M., Maddahi A., Bari F., Edvinsson L. VIP/PACAP receptors in cerebral arteries of rat: characterization, localization and relation to intracellular calcium. Neuropeptides 2013, 47:85-92.
49. Evans B.N., Rosenblatt M.I., Mnayer L.O., Oliver K.R., Dickerson I.M. CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors. J. Biol. Chem. 2000, 275:31438-31443.
50. Fahrenkrug J., Hannibal J. Localisation of the neuropeptide PACAP and its receptors in the rat parathyroid and thyroid glands. Gen. Comp. Endocrinol. 2011, 171:105-113.
51. Fahrenkrug J., Hannibal J., Tams J., Georg B. Immunohistochemical localization of the VIP1 receptor (VPAC1R) in rat cerebral blood vessels: relation to PACAP and VIP containing nerves. J. Cereb. Blood Flow Metabol. 2000, 20:1205-1214.
52. Fischer M.J. Calcitonin gene-related peptide receptor antagonists for migraine. Expert Opin. Investig. Drugs 2010, 19:815-823.
53. Gallai V., Sarchielli P., Floridi A., Franceschini M., Codini M., Glioti G., Trequattrini A., Palumbo R. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 1995, 15:384-390.
54. Gauriau C., Bernard J.F. Posterior triangular thalamic neurons convey nociceptive messages to the secondary somatosensory and insular cortices in the rat. J. Neurosci. 2004, 24:752-761.
55. Goadsby P.J. Can we develop neurally acting drugs for the treatment of migraine?. Nat. Rev. Drug Discov. 2005, 4:741-750.
56. Goadsby P.J. Migraine: emerging treatment options for preventive and acute attack therapy. Expert Opin. Emerg. Drugs 2006, 11:419-427.
57. Goadsby P.J. The vascular theory of migraine - a great story wrecked by the facts. Brain 2009, 132:6-7.
58. Goadsby P.J., Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol. 1993, 33:48-56.
59. Goadsby P.J., Edvinsson L., Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann. Neurol. 1988, 23:193-196.
60. Goadsby P.J., Edvinsson L., Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol. 1990, 28:183-187.
61. Goadsby P.J., Lipton R.B., Ferrari M.D. Migraine - current understanding and treatment. N. Engl. J. Med. 2002, 346:257-270.
62. Gu X.L., Yu L.C. The colocalization of CGRP receptor and AMPA receptor in the spinal dorsal horn neuron of rat: a morphological and electrophysiological study. Neurosci. Lett. 2007, 414:237-241.
63. Hammack S.E., Cheung J., Rhodes K.M., Schutz K.C., Falls W.A., Braas K.M., May V. Chronic stress increases pituitary adenylate cyclase-activating peptide (PACAP) and brain-derived neurotrophic factor (BDNF) mRNA expression in the bed nucleus of the stria terminalis (BNST): roles for PACAP in anxiety-like behavior. Psychoneuroendocrinology 2009, 34:833-843.
64. Hammack S.E., Roman C.W., Lezak K.R., Kocho-Shellenberg M., Grimmig B., Falls W.A., Braas K., May V. Roles for pituitary adenylate cyclase-activating peptide (PACAP) expression and signaling in the bed nucleus of the stria terminalis (BNST) in mediating the behavioral consequences of chronic stress. J. Mol. Neurosci. 2010, 42:327-340.
65. Hansen J.M., Hauge A.W., Olesen J., Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia 2010, 30:1179-1186.
66. Hansson E., Ronnback L. Glial neuronal signaling in the central nervous system. FASEB J. 2003, 17:341-348.
67. Hashimoto H., Shintani N., Baba A. New insights into the central PACAPergic system from the phenotypes in PACAP- and PACAP receptor-knockout mice. Ann. N.Y. Acad. Sci. 2006, 1070:75-89.
68. Hattori S., Takao K., Tanda K., Toyama K., Shintani N., Baba A., Hashimoto H., Miyakawa T. Comprehensive behavioral analysis of pituitary adenylate cyclase-activating polypeptide (PACAP) knockout mice. Front. Behav. Neurosci. 2012, 6:58.
69. Hawkins K., Wang S., Rupnow M.F. Indirect cost burden of migraine in the United States. J. Occup. Environ. Med. 2007, 49:368-374.
70. Hawkins K., Wang S., Rupnow M. Direct cost burden among insured us employees with migraine. Headache 2008, 48:553-563.
71. Hay D.L., Christopoulos G., Christopoulos A., Sexton P.M. Determinants of 1-piperidinecarboxamide, n-[2-[[5-amino-l-[[4-(4-pyridinyl)-l-piperazinyl]carbonyl]pentyl]amino]-1-[(3,5-d ibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2h)-quinazoliny l) (BIBN4096BS) affinity for calcitonin gene-related peptide and amylin receptors - the role of receptor activity modifying protein 1. Mol. Pharmacol. 2006, 70:1984-1991.
72. Headache C.S.o.t.I.H.S. The international classification of headache disorders: 2nd edition. Cephalalgia 2004, 24(Suppl. 1):9-160.
73. Helyes Z., Pozsgai G., Borzsei R., Nemeth J., Bagoly T., Mark L., Pinter E., Toth G., Elekes K., Szolcsanyi J., Reglodi D. Inhibitory effect of PACAP-38 on acute neurogenic and non-neurogenic inflammatory processes in the rat. Peptides 2007, 28:1847-1855.
74. Heroux M., Hogue M., Lemieux S., Bouvier M. Functional calcitonin gene-related peptide receptors are formed by the asymmetric assembly of a calcitonin receptor-like receptor homo-oligomer and a monomer of receptor activity-modifying protein-1. J. Biol. Chem. 2007, 282:31610-31620.
75. Ho T.W., Ferrari M.D., Dodick D.W., Galet V., Kost J., Fan X., Leibensperger H., Froman S., Assaid C., Lines C., Koppen H., Winner P.K. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008, 372:2115-2123.
76. Ho T.W., Mannix L.K., Fan X., Assaid C., Furtek C., Jones C.J., Lines C.R., Rapoport A.M. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008, 70:1304-1312.
77. Ho T.W., Edvinsson L., Goadsby P.J. CGRP and its receptors provide new insights into migraine pathophysiology. Nat. Rev. Neurol. 2010, 6:573-582.
78. Holzer P. Neurogenic vasodilatation and plasma leakage in the skin. Gen. Pharmacol. 1998, 30:5-11.
79. Hoskin K.L., Zagami A.S., Goadsby P.J. Stimulation of the middle meningeal artery leads to fos expression in the trigeminocervical nucleus: a comparative study of monkey and cat. J. Anatomy 1999, 194(Pt 4):579-588.
80. Hu X.H., Markson L.E., Lipton R.B., Stewart W.F., Berger M.L. Burden of migraine in the United States: disability and economic costs. Arch. Int. Med. 1999, 159:813-818.
81. Huang Y., Brodda-Jansen G., Lundeberg T., Yu L.C. Anti-nociceptive effects of calcitonin gene-related peptide in nucleus raphe magnus of rats: an effect attenuated by naloxone. Brain Res. 2000, 873:54-59.
82. Huang R., Karve A., Shah I., Bowers M.C., DiPette D.J., Supowit S.C., Abela G.S. Deletion of the mouse alpha-calcitonin gene-related peptide gene increases the vulnerability of the heart to ischemia-reperfusion injury. Am. J. Physiol. 2008, 294:H1291-H1297.
83. Iversen H.K., Olesen J., Tfelt-Hansen P. Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain 1989, 38:17-24.
84. Jenkins D.W., Langmead C.J., Parsons A.A., Strijbos P.J. Regulation of calcitonin gene-related peptide release from rat trigeminal nucleus caudalis slices in vitro. Neurosci. Lett. 2004, 366:241-244.
85. Juhasz G., Zsombok T., Modos E.A., Olajos S., Jakab B., Nemeth J., Szolcsanyi J., Vitrai J., Bagdy G. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 2003, 106:461-470.
86. Juhasz G., Zsombok T., Jakab B., Nemeth J., Szolcsanyi J., Bagdy G. Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. Cephalalgia 2005, 25:179-183.
87. Kaiser E.A., Kuburas A., Recober A., Russo A.F. Modulation of CGRP-induced light aversion in wild-type mice by a 5-HT(1B/D) agonist. J. Neurosci. 2012, 32:15439-15449.
88. Kaube H., Keay K.A., Hoskin K.L., Bandler R., Goadsby P.J. Expression of c-fos-like immunoreactivity in the caudal medulla and upper cervical spinal cord following stimulation of the superior sagittal sinus in the cat. Brain Res. 1993, 629:95-102.
89. Kelman L. The aura: a tertiary care study of 952 migraine patients. Cephalalgia 2004, 24:728-734.
90. Kelman L. The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. Headache 2004, 44:865-872.
91. Koulchitsky S., Fischer M.J., De Col R., Schlechtweg P.M., Messlinger K. Biphasic response to nitric oxide of spinal trigeminal neurons with meningeal input in rat - possible implications for the pathophysiology of headaches. J. Neurophysiol. 2004, 92:1320-1328.
92. Koves K., Arimura A., Somogyvari-Vigh A., Vigh S., Miller J. Immunohistochemical demonstration of a novel hypothalamic peptide, pituitary adenylate cyclase-activating polypeptide, in the ovine hypothalamus. Endocrinology 1990, 127:264-271.
93. Kresse A., Jacobowitz D.M., Skofitsch G. Detailed mapping of CGRP mRNA expression in the rat central nervous system: comparison with previous immunocytochemical findings. Brain Res. Bull. 1995, 36:261-274.
94. Kunkler P.E., Kraig R.P. Hippocampal spreading depression bilaterally activates the caudal trigeminal nucleus in rodents. Hippocampus 2003, 13:835-844.
95. Laburthe M., Couvineau A. Molecular pharmacology and structure of VPAC receptors for VIP and PACAP. Regul. Peptides 2002, 108:165-173.
96. Lambert G.A. The lack of peripheral pathology in migraine headache. Headache 2010, 50:895-908.
97. Lambert G.A., Zagami A.S. The mode of action of migraine triggers: a hypothesis. Headache 2009, 49:253-275.
98. Lassen L.H., Thomsen L.L., Olesen J. Histamine induces migraine via the H1-receptor. Support for the NO hypothesis of migraine. NeuroReport 1995, 6:1475-1479.
99. Lassen L.H., Haderslev P.A., Jacobsen V.B., Iversen H.K., Sperling B., Olesen J. CGRP may play a causative role in migraine. Cephalalgia 2002, 22:54-61.
100. Lassen L.H., Jacobsen V.B., Haderslev P.A., Sperling B., Iversen H.K., Olesen J., Tfelt-Hansen P. Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients. J. Headache Pain 2008, 9:151-157.
101. Lee Y., Takami K., Kawai Y., Girgis S., Hillyard C.J., MacIntyre I., Emson P.C., Tohyama M. Distribution of calcitonin gene-related peptide in the rat peripheral nervous system with reference to its coexistence with substance P. Neuroscience 1985, 15:1227-1237.
102. Lennerz J.K., Ruhle V., Ceppa E.P., Neuhuber W.L., Bunnett N.W., Grady E.F., Messlinger K. Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J. Comp. Neurol. 2008, 507:1277-1299.
103. Levy D. Migraine pain and nociceptor activation - where do we stand?. Headache 2010, 50:909-916.
104. Levy D., Burstein R. The vascular theory of migraine: leave it or love it?. Ann. Neurol. 2011, 69:600-601.
105. Levy D., Jakubowski M., Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc. Natl. Acad. Sci. USA 2004, 101:4274-4279.
106. Levy D., Burstein R., Kainz V., Jakubowski M., Strassman A.M. Mast cell degranulation activates a pain pathway underlying migraine headache. Pain 2007, 130:166-176.
107. Lipton R.B., Stewart W.F., Diamond S., Diamond M.L., Reed M. Prevalence and burden of migraine in the United States: data from the American migraine study II. Headache 2001, 41:646-657.
108. Liu Y., Broman J., Edvinsson L. Central projections of the sensory innervation of the rat middle meningeal artery. Brain Res. 2008, 1208:103-110.
109. Loder E. Triptan therapy in migraine. N. Engl. J. Med. 2010, 363:63-70.
110. Lundberg J.M., Franco-Cereceda A., Hua X., Hokfelt T., Fischer J.A. Co-existence of substance p and calcitonin gene-related peptide-like immunoreactivities in sensory nerves in relation to cardiovascular and bronchoconstrictor effects of capsaicin. Eur. J. Pharmacol. 1985, 108:315-319.
111. Ma W., Chabot J.G., Powell K.J., Jhamandas K., Dickerson I.M., Quirion R. Localization and modulation of calcitonin gene-related peptide-receptor component protein-immunoreactive cells in the rat central and peripheral nervous systems. Neuroscience 2003, 120:677-694.
112. Markovics A., Kormos V., Gaszner B., Lashgarara A., Szoke E., Sandor K., Szabadfi K., Tuka B., Tajti J., Szolcsanyi J., Pinter E., Hashimoto H., Kun J., Reglodi D., Helyes Z. Pituitary adenylate cyclase-activating polypeptide plays a key role in nitroglycerol-induced trigeminovascular activation in mice. Neurobiol. Disease 2012, 45:633-644.
113. Markowitz S., Saito K., Moskowitz M.A. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J. Neurosci. 1987, 7:4129-4136.
114. Marquez de Prado B., Hammond D.L., Russo A.F. Genetic enhancement of calcitonin gene-related peptide-induced central sensitization to mechanical stimuli in mice. J. Pain 2009, 10:992-1000.
115. Martin R.S., Martin G.R. Investigations into migraine pathogenesis: time course for effects of m-cpp, bw723c86 or glyceryl trinitrate on appearance of fos-like immunoreactivity in rat trigeminal nucleus caudalis (TNC). Cephalalgia 2001, 21:46-52.
116. Masuo Y., Ohtaki T., Masuda Y., Tsuda M., Fujino M. Binding sites for pituitary adenylate cyclase activating polypeptide (PACAP): comparison with vasoactive intestinal polypeptide (VIP) binding site localization in rat brain sections. Brain Res. 1992, 575:113-123.
117. McCulloch J., Uddman R., Kingman T.A., Edvinsson L. Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc. Natl. Acad. Sci. USA 1986, 83:5731-5735.
118. McLatchie L.M., Fraser N.J., Main M.J., Wise A., Brown J., Thompson N., Solari R., Lee M.G., Foord S.M. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998, 393:333-339.
119. Menon S., Buteri J., Roy B., Murrell M., Quinlan S., Macmillan J.C., Lea R.A., Haupt L.M., Griffiths L.R. Association study of calcitonin gene-related polypeptide-alpha (CALCA) gene polymorphism with migraine. Brain Res. 2011, 1378:119-124.
120. Messlinger K. Migraine: where and how does the pain originate?. Exp. Brain Res. 2009, 196:179-193.
121. Messlinger K., Hanesch U., Baumgartel M., Trost B., Schmidt R.F. Innervation of the dura mater encephali of cat and rat: ultrastructure and calcitonin gene-related peptide-like and substance P-like immunoreactivity. Anat. Embryol. 1993, 188:219-237.
122. Moreno M.J., Abounader R., Hebert E., Doods H., Hamel E. Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment. Neuropharmacology 2002, 42:568-576.
123. Morfis M., Christopoulos A., Sexton P.M. RAMPs: 5years on, where to now?. Trends Pharmacol. Sci. 2003, 24:596-601.
124. Moskowitz M.A. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 1993, 43:S16-S20.
125. Moya F., Nieto A., JL R.C. Calcitonin biosynthesis: evidence for a precursor. Eur. J. Biochem. 1975, 55:407-413.
126. Narita M., Dun S.L., Dun N.J., Tseng L.F. Hyperalgesia induced by pituitary adenylate cyclase-activating polypeptide in the mouse spinal cord. Eur. J. Pharmacol. 1996, 311:121-126.
127. Nemeth J., Reglodi D., Pozsgai G., Szabo A., Elekes K., Pinter E., Szolcsanyi J., Helyes Z. Effect of pituitary adenylate cyclase activating polypeptide-38 on sensory neuropeptide release and neurogenic inflammation in rats and mice. Neuroscience 2006, 143:223-230.
128. Noseda R., Kainz V., Jakubowski M., Gooley J.J., Saper C.B., Digre K., Burstein R. A neural mechanism for exacerbation of headache by light. Nat. Neurosci. 2010, 13:239-245.
129. Offenhauser N., Zinck T., Hoffmann J., Schiemann K., Schuh-Hofer S., Rohde W., Arnold G., Dirnagl U., Jansen-Olesen I., Reuter U. CGRP release and c-fos expression within trigeminal nucleus caudalis of the rat following glyceryltrinitrate infusion. Cephalalgia 2005, 25:225-236.
130. Olesen J., Diener H.C., Husstedt I.W., Goadsby P.J., Hall D., Meier U., Pollentier S., Lesko L.M. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med. 2004, 350:1104-1110.
131. Olesen J., Burstein R., Ashina M., Tfelt-Hansen P. Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol. 2009, 8:679-690.
132. Oliver K.R., Wainwright A., Edvinsson L., Pickard J.D., Hill R.G. Immunohistochemical localization of calcitonin receptor-like receptor and receptor activity-modifying proteins in the human cerebral vasculature. J. Cereb. Blood Flow Metabol. 2002, 22:620-629.
133. Otto C., Martin M., Wolfer D.P., Lipp H.P., Maldonado R., Schutz G. Altered emotional behavior in PACAP-type-I-receptor-deficient mice. Brain Res. Mol. Brain Res. 2001, 92:78-84.
134. Ottosson A., Edvinsson L. Release of histamine from dural mast cells by substance P and calcitonin gene-related peptide. Cephalalgia 1997, 17:166-174.
135. Petersen K.A., Lassen L.H., Birk S., Lesko L., Olesen J. Bibn4096bs antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin. Pharmacol. Ther. 2005, 77:202-213.
136. Pietrobon D., Striessnig J. Neurobiology of migraine. Nat. Rev. Neurosci. 2003, 4:386-398.
137. Prado M.A., Evans-Bain B., Dickerson I.M. Receptor component protein (rcp): a member of a multi-protein complex required for g-protein-coupled signal transduction. Biochem. Soc. Trans. 2002, 30:460-464.
138. Purdy R.A. The role of the visual system in migraine: an update. Neurol. Sci. 2011, 32(Suppl 1):S89-S93.
139. Raddant A.C., Russo A.F. Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation. Expert Rev. Mol. Med. 2011, 13:e36.
140. Rahmann A., Wienecke T., Hansen J.M., Fahrenkrug J., Olesen J., Ashina M. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia 2008, 28:226-236.
141. Rapoport A.M. New acute treatments for headache. Neurol. Sci. 2010, 31(Suppl 1):S129-S132.
142. Recober A., Russo A.F. Calcitonin gene-related peptide: an update on the biology. Curr. Opin. Neurol. 2009, 22:241-246.
143. Recober A., Kuburas A., Zhang Z., Wemmie J.A., Anderson M.G., Russo A.F. Role of calcitonin gene-related peptide in light-aversive behavior: implications for migraine. J. Neurosci. 2009, 29:8798-8804.
144. Recober A., Kaiser E.A., Kuburas A., Russo A.F. Induction of multiple photophobic behaviors in a transgenic mouse sensitized to CGRP. Neuropharmacology 2010, 58:156-165.
145. Reglodi D., Kiss P., Horvath G., Lubics A., Laszlo E., Tamas A., Racz B., Szakaly P. Effects of pituitary adenylate cyclase activating polypeptide in the urinary system, with special emphasis on its protective effects in the kidney. Neuropeptides 2012, 46:61-70.
146. Robert C., Bourgeais L., Arreto C.D., Condes-Lara M., Noseda R., Jay T., Villanueva L. Paraventricular hypothalamic regulation of trigeminovascular mechanisms involved in headaches. J. Neurosci. 2013, 33:8827-8840.
147. Russo A.F., Nelson C., Roos B.A., Rosenfeld M.G. Differential regulation of the coexpressed calcitonin/alpha-CGRP and beta-CGRP neuroendocrine genes. J. Biol. Chem. 1988, 263:5-8.
148. Russo A.F., Kuburas A., Kaiser E.A., Raddant A.C., Recober A. A potential preclinical migraine model: CGRP-sensitized mice. Mol. Cell. Pharmacol. 2009, 1:264-270.
149. Sandor K., Bolcskei K., McDougall J.J., Schuelert N., Reglodi D., Elekes K., Petho G., Pinter E., Szolcsanyi J., Helyes Z. Divergent peripheral effects of pituitary adenylate cyclase-activating polypeptide-38 on nociception in rats and mice. Pain 2009, 141:143-150.
150. Sandor K., Kormos V., Botz B., Imreh A., Bolcskei K., Gaszner B., Markovics A., Szolcsanyi J., Shintani N., Hashimoto H., Baba A., Reglodi D., Helyes Z. Impaired nocifensive behaviours and mechanical hyperalgesia, but enhanced thermal allodynia in pituitary adenylate cyclase-activating polypeptide deficient mice. Neuropeptides 2010, 44:363-371.
151. Schoonman G.G., van der Grond J., Kortmann C., van der Geest R.J., Terwindt G.M., Ferrari M.D. Migraine headache is not associated with cerebral or meningeal vasodilatation - a 3T magnetic resonance angiography study. Brain 2008, 131:2192-2200.
152. Schwedt T.J., Goadsby P.J. 14th international headache congress: basic science highlights. Headache 2010, 50:520-526.
153. Schytz H.W., Birk S., Wienecke T., Kruuse C., Olesen J., Ashina M. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 2009, 132:16-25.
154. Schytz H.W., Olesen J., Ashina M. The PACAP receptor: a novel target for migraine treatment. Neurotherapeutics 2010, 7:191-196.
155. Seybold V.S. The role of peptides in central sensitization. Handbook Exp. Pharmacol. 2009, 451-491.
156. Silberstein S.D., Goadsby P.J. Migraine: preventive treatment. Cephalalgia 2002, 22:491-512.
157. Skofitsch G., Jacobowitz D.M. Autoradiographic distribution of 125I calcitonin gene-related peptide binding sites in the rat central nervous system. Peptides 1985, 6:975-986.
158. Skofitsch G., Jacobowitz D.M. Calcitonin gene-related peptide coexists with substance P in capsaicin sensitive neurons and sensory ganglia of the rat. Peptides 1985, 6:747-754.
159. Stewart W.F., Wood C., Reed M.L., Roy J., Lipton R.B. Cumulative lifetime migraine incidence in women and men. Cephalalgia 2008, 28:1170-1178.
160. Strassman A., Mason P., Moskowitz M., Maciewicz R. Response of brainstem trigeminal neurons to electrical stimulation of the dura. Brain Res. 1986, 379:242-250.
161. Strassman A.M., Raymond S.A., Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996, 384:560-564.
162. Strecker T., Dux M., Messlinger K. Nitric oxide releases calcitonin-gene-related peptide from rat dura mater encephali promoting increases in meningeal blood flow. J. Vasc. Res. 2002, 39:489-496.
163. Summ O., Charbit A.R., Andreou A.P., Goadsby P.J. Modulation of nocioceptive transmission with calcitonin gene-related peptide receptor antagonists in the thalamus. Brain 2010, 133:2540-2548.
164. Syed A.U., Koide M., Braas K.M., May V., Wellman G.C. Pituitary adenylate cyclase-activating polypeptide (PACAP) potently dilates middle meningeal arteries: implications for migraine. J. Mol. Neurosci. 2012, 48:574-583.
165. Tajti J., Uddman R., Moller S., Sundler F., Edvinsson L. Messenger molecules and receptor mRNA in the human trigeminal ganglion. J. Auton. Nerv. Syst. 1999, 76:176-183.
166. Tajti J., Uddman R., Edvinsson L. Neuropeptide localization in the "migraine generator" region of the human brainstem. Cephalalgia 2001, 21:96-101.
167. Tassorelli C., Joseph S.A. NADPH-diaphorase activity and fos expression in brain nuclei following nitroglycerin administration. Brain Res. 1995, 695:37-44.
168. Tassorelli C., Joseph S.A. Systemic nitroglycerin induces fos immunoreactivity in brainstem and forebrain structures of the rat. Brain Res. 1995, 682:167-181.
169. Tfelt-Hansen P., Le H. Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache? A review. J. Headache Pain 2009, 10:137-143.
170. Tfelt-Hansen P., Olesen J. Taking the negative view of current migraine treatments: the unmet needs. CNS Drugs 2012, 26:375-382.
171. Thalakoti S., Patil V.V., Damodaram S., Vause C.V., Langford L.E., Freeman S.E., Durham P.L. Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache 2007, 47:1008-1023.
172. Theoharides T.C., Donelan J., Kandere-Grzybowska K., Konstantinidou A. The role of mast cells in migraine pathophysiology. Brain Res. Brain Res. Rev. 2005, 49:65-76.
173. Tozzi A., de Iure A., Di Filippo M., Costa C., Caproni S., Pisani A., Bonsi P., Picconi B., Cupini L.M., Materazzi S., Geppetti P., Sarchielli P., Calabresi P. Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. Proc. Natl. Acad. Sci. USA 2012, 109:18985-18990.
174. Tuka B., Helyes Z., Markovics A., Bagoly T., Nemeth J., Mark L., Brubel R., Reglodi D., Pardutz A., Szolcsanyi J., Vecsei L., Tajti J. Peripheral and central alterations of pituitary adenylate cyclase activating polypeptide-like immunoreactivity in the rat in response to activation of the trigeminovascular system. Peptides 2012, 33:307-316.
175. Tuka B., Helyes Z., Markovics A., Bagoly T., Szolcsanyi J., Szabo N., Toth E., Kincses Z.T., Vecsei L., Tajti J. Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Cephalalgia 2013, 33:1085-1095.
176. Tvedskov J.F., Lipka K., Ashina M., Iversen H.K., Schifter S., Olesen J. No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann. Neurol. 2005, 58:561-568.
177. Uddman R., Tajti J., Hou M., Sundler F., Edvinsson L. Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2. Cephalalgia 2002, 22:112-116.
178. van Rossum D., Hanisch U.K., Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci. Biobehav. Rev. 1997, 21:649-678.
179. Vaudry D., Gonzalez B.J., Basille M., Yon L., Fournier A., Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol. Rev. 2000, 52:269-324.
180. Vause C.V., Durham P.L. Calcitonin gene-related peptide differentially regulates gene and protein expression in trigeminal glia cells: findings from array analysis. Neurosci. Lett. 2010, 473:163-167.
181. Villalon C.M., Olesen J. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol. Ther. 2009, 124:309-323.
182. Waeber C., Moskowitz M.A. Migraine as an inflammatory disorder. Neurology 2005, 64:S9-S15.
183. Wahl M., Schilling L., Parsons A.A., Kaumann A. Involvement of calcitonin gene-related peptide (CGRP) and nitric oxide (NO) in the pial artery dilatation elicited by cortical spreading depression. Brain Res. 1994, 637:204-210.
184. Walker C.S., Conner A.C., Poyner D.R., Hay D.L. Regulation of signal transduction by calcitonin gene-related peptide receptors. Trends Pharmacol. Sci. 2010, 31:476-483.
185. Watkins L.R., Milligan E.D., Maier S.F. Spinal cord glia: new players in pain. Pain 2001, 93:201-205.
186. Wimalawansa S.J. Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr. Rev. 1996, 17:533-585.
187. Wolff H.G., Tunis M.M., Goodell H. Studies on headache; evidence of damage and changes in pain sensitivity in subjects with vascular headaches of the migraine type. A.M.A. Arch. Int. Med. 1953, 92:478-484.
188. Yan J., Edelmayer R.M., Wei X., De Felice M., Porreca F., Dussor G. Dural afferents express acid-sensing ion channels: a role for decreased meningeal pH in migraine headache. Pain 2011, 152:106-113.
189. Yashpal K., Kar S., Dennis T., Quirion R. Quantitative autoradiographic distribution of calcitonin gene-related peptide (hCGRP alpha) binding sites in the rat and monkey spinal cord. J. Comp. Neurol. 1992, 322:224-232.
190. Zhang Y., Danielsen N., Sundler F., Mulder H. Pituitary adenylate cyclase-activating peptide is upregulated in sensory neurons by inflammation. NeuroReport 1998, 9:2833-2836.
191. Zhang Z., Dickerson I.M., Russo A.F. Calcitonin gene-related peptide receptor activation by receptor activity-modifying protein-1 gene transfer to vascular smooth muscle cells. Endocrinology 2006, 147:1932-1940.
192. Zhang Z., Winborn C.S., Marquez de Prado B., Russo A.F. Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J. Neurosci. 2007, 27:2693-2703.
193. Zhang X., Levy D., Noseda R., Kainz V., Jakubowski M., Burstein R. Activation of meningeal nociceptors by cortical spreading depression: implications for migraine with aura. J. Neurosci. 2010, 30:8807-8814.
194. Zhang X., Levy D., Kainz V., Noseda R., Jakubowski M., Burstein R. Activation of central trigeminovascular neurons by cortical spreading depression. Ann. Neurol. 2011, 69:855-865.